Revolution Medicines, Inc. (RVMD)
NASDAQ: RVMD · Real-Time Price · USD
38.34
+0.30 (0.79%)
At close: Aug 28, 2025, 4:00 PM
38.33
-0.02 (-0.04%)
After-hours: Aug 28, 2025, 4:00 PM EDT
Revolution Medicines Employees
Revolution Medicines had 534 employees as of December 31, 2024. The number of employees increased by 156 or 41.27% compared to the previous year.
Employees
534
Change (1Y)
156
Growth (1Y)
41.27%
Revenue / Employee
n/a
Profits / Employee
-$1,520,712
Market Cap
7.17B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 534 | 156 | 41.27% |
| Dec 31, 2023 | 378 | 132 | 53.66% |
| Dec 31, 2022 | 246 | 58 | 30.85% |
| Dec 31, 2021 | 188 | 63 | 50.40% |
| Dec 31, 2020 | 125 | 30 | 31.58% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
RVMD News
- 21 days ago - Revolution Medicines, Inc. (RVMD) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Revolution Medicines Reports Second Quarter 2025 Financial Results and Update on Corporate Progress - GlobeNewsWire
- 4 weeks ago - Revolution Medicines to Report Financial Results for Second Quarter 2025 After Market Close on August 6, 2025 - GlobeNewsWire
- 5 weeks ago - Revolution Medicines Announces Publication of a Peer-Reviewed Research Paper in Science on the Discovery and Development of Zoldonrasib, a RAS(ON) G12D-Selective Inhibitor - GlobeNewsWire
- 5 weeks ago - Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib - GlobeNewsWire
- 7 weeks ago - Revolution Medicines and Iambic Announce Technology and Research Collaboration Using Iambic's AI Discovery Tools to Pursue New Drug Candidates - GlobeNewsWire
- 2 months ago - Revolution Medicines and Summit Therapeutics Enter into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors with Ivonescimab in RAS Mutant Tumors - GlobeNewsWire
- 2 months ago - Revolution Medicines and Summit Therapeutics Enter Into Clinical Collaboration to Evaluate Combinations of Three RAS(ON) Inhibitors With Ivonescimab in RAS Mutant Tumors - Business Wire